Topic: Clinical Trial Results
The IL-23 antibody easily outperformed J&J’s Stelara and AbbVie’s own Humira, setting it up to go before regulators next year.
The study linked synthetic oral endocannabinoid-mimetic anabasum to a statistically significant drop on a skin disease scale.
The TRK TKI achieved a median duration of response of 28.6 months, suggesting its effect may last longer than that of the incumbent.
The data tee Motif Bio up to file for approval of a drug that was knocked back by the FDA in 2009 and almost sunk the biotech 12 months ago.
The trial linked the single-domain antibody to a significant drop in time to platelet count response, bolstering Ablynx’s pitch for approval.
More than half of subjects who took the hydrogel particles lost weight, encouraging Gelesis to file for approval despite missing another endpoint.
Versartis’ somavaratan has failed to match Pfizer’s Genotropin in phase 3, wiping more than 80% off its stock price.
In our EuroBiotech roundup this week, Autolus advances CAR-T trial, Cell Medica names CSO and AB Science suffers a regulatory setback.
The clean sweep is a big win for Alnylam and the Sanofi-partnered RNAi drug, which is now set to be put before regulators at the end of the year.
The red-blood-cell-encapsulated L-asparaginase improved overall survival and other outcomes in metastatic pancreatic cancer patients.